Chemistry42 is a software platform for de novo small molecule design that integrates Artificial Intelligence (AI) techniques with computational and medicinal chemistry methods. Chemistry42 is unique in its ability to generate novel molecular structures with predefined properties validated through in vitro and in vivo studies. Chemistry42 is a core component of Insilico Medicine Pharma.ai drug discovery suite that also includes target discovery and multi-omics data analysis (PandaOmics) and clinical trial outcomes predictions (InClinico).
Cite
@article{arxiv.2101.09050,
title = {Chemistry42: An AI-based platform for de novo molecular design},
author = {Yan A. Ivanenkov and Alex Zhebrak and Dmitry Bezrukov and Bogdan Zagribelnyy and Vladimir Aladinskiy and Daniil Polykovskiy and Eugene Lane and Petrina Kamya and Alexander Aliper and Alex Zhavoronkov},
journal= {arXiv preprint arXiv:2101.09050},
year = {2025}
}